A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry

| GregoryGregory | 0 Comment
A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry
Because of the rising variety of therapeutic monoclonal antibodies (mAbs) used within the clinic, there’s an rising want for sturdy analytical strategies to quantify complete mAb concentrations in human plasma for medical research and therapeutic drug monitoring.
We developed a simple, fast, and sturdy pattern preparation methodology for liquid chromatography-tandem mass spectrometry (LC-MS/MS) evaluation. The tactic was validated for infliximab (IFX), rituximab (RTX), cetuximab (CTX), dupilumab (DPL), dinutuximab (DNX), vedolizumab (VDZ), and emicizumab (EMZ). Saturated ammonium sulfate (AS) was used to precipitate immunoglobulins in human plasma.
After centrifugation, supernatant containing albumin was decanted, and the precipitated immunoglobulin fraction was re-dissolved in buffer containing 6M guanidine. This fraction was then utterly denatured, lowered, alkylated, and trypsin digested. Lastly, signature peptides from the seven mAbs had been concurrently quantified on LC-MS/MS along with their inside requirements secure isotopically labeled peptide counterparts.
The linear dynamic ranges (1 – 512 mg/L) of IFX, CTX, RTX, and EMZ confirmed wonderful (R2 > 0.999) linearity and people of DPL, DNX, and VDZ confirmed good (R2 > 0.995) linearity. The tactic was validated in accordance with the EMA tips. EDTA plasma, sodium citrate plasma, heparin plasma, and serum yielded comparable outcomes.
Ready samples had been secure at room temperature (20°C) and at 5°C for three days, and confirmed no decline in focus for all examined mAbs. This described methodology, which has the benefit of a simple, fast, and sturdy pre-analytical pattern preparation, can be utilized as a template to quantify different mAbs in human plasma or serum.

Reactions and COVID-19 illness development following SARS-CoV-2 monoclonal antibody infusion

SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a remedy for gentle to average COVID-19, with favorable outcomes reported in medical trials and an emergency use authorization granted by the Meals and Drug Administration. Actual-world knowledge stay restricted, nevertheless, and thus this evaluation presents findings from over 6,500 outpatient administrations of mAb at services affiliated with a big healthcare group in the US.
Inside 48 hours of mAb infusion, 15.6% (1,043) of sufferers obtained a drug that was indicative of a potential response to the infusion; the vast majority of these had been gentle (e.g., acetaminophen). Roughly 5.2% of sufferers who obtained mAb (n=347) had a post-infusion emergency division go to or admission for COVID-19 illness development.
The outcomes of this evaluation point out that sufferers who obtain mAb have a low chance of each an instantaneous detrimental response to the remedy in addition to future inpatient admission associated to COVID-19 illness development.

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable web site

Potent neutralizing SARS-CoV-2 antibodies typically goal the spike protein receptor-binding web site (RBS), however the variability of RBS epitopes hampers broad neutralization of a number of sarbecoviruses and drifted viruses. Right here, utilizing humanized mice, we recognized an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, together with SARS-CoV and SARS-CoV-2 variants.
X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved websites and the sunshine chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimal footprints within the hypervariable area of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching.
The coordinated binding resulted in broad neutralization of SARS-CoV and rising SARS-CoV-2 variants of concern. Low-dose therapeutic antibody remedy in hamsters lowered the virus titers and morbidity throughout SARS-CoV-2 problem. The structural foundation for broad neutralizing exercise could inform the design of a broad spectrum of therapeutics and vaccines.

Pharmacodynamic measures inside tumors expose differential exercise of PD(L)-1 antibody therapeutics

Macromolecules reminiscent of monoclonal antibodies (mAbs) are prone to expertise poor tumor penetration due to their massive dimension, and thus low drug publicity of goal cells inside a tumor might contribute to suboptimal responses. Given the problem of insufficient quantitative instruments to evaluate mAb exercise inside tumors, we hypothesized that measurement of accessible goal ranges in tumors might elucidate the pharmacologic exercise of a mAb and might be used to match the exercise of various mAbs.
Utilizing positron emission tomography (PET), we measured the pharmacodynamics of immune checkpoint protein programmed-death ligand 1 (PD-L1) to guage pharmacologic results of mAbs concentrating on PD-L1 and its receptor programmed cell demise protein 1 (PD-1). For PD-L1 quantification, we first developed a small peptide-based fluorine-18-labeled PET imaging agent, [18F]DK222, which supplied high-contrast pictures in preclinical fashions.
We then quantified accessible PD-L1 ranges within the tumor mattress throughout remedy with anti-PD-1 and anti-PD-L1 mAbs. Making use of mixed-effects fashions to those knowledge, we discovered delicate variations within the pharmacodynamic results of two anti-PD-1 mAbs (nivolumab and pembrolizumab).
In distinction, we noticed starkly divergent goal engagement with anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab) that had been administered at equal doses, correlating with differential results on tumor development. Thus, we present that measuring PD-L1 pharmacodynamics informs mechanistic understanding of therapeutic mAbs concentrating on PD-L1 and PD-1.
These findings exhibit the worth of quantifying goal pharmacodynamics to elucidate the pharmacologic exercise of mAbs, unbiased of mAb biophysical properties and inclusive of all physiological variables, that are extremely heterogeneous inside and throughout tumors and sufferers.

Ehrlichia chaffeensis and E. canis hypothetical protein immunoanalysis reveals small secreted immunodominant proteins and conformation-dependent antibody epitopes

Immunomolecular characterization of Ehrlichia chaffeensis (E. ch.) and E. canis (E. ca.) has outlined protein orthologs, together with tandem repeat proteins (TRPs) which have immunodominant linear antibody epitopes. On this examine, we mixed bioinformatic evaluation and cell-free protein expression to determine undiscovered immunoreactive E. ch. and E. ca. hypothetical proteins.
Antigenicity of the E. ch. and E. ca. ORFeomes (n = 1105 and n = 925, respectively) was analyzed by the sequence-based prediction mannequin ANTIGENpro, and we recognized ~250 ORFs in every respective ORFeome as extremely antigenic. The hypothetical proteins (E. ch. n = 93 and E. ca. n = 98) current within the prime 250 antigenic ORFs had been additional investigated on this examine. By ELISA, 46 E. ch. and 30 E. ca.
IVTT-expressed hypothetical proteins reacted with antibodies in sera from naturally E. ch.-infected sufferers or E. ca.-infected canine. Furthermore, 15 E. ch. and 16 E. ca. proteins persistently reacted with a panel of sera from sufferers or canine, together with many that exposed the immunoreactivity of “gold commonplace” TRPs. Antibody epitopes in most (>70%) of those proteins exhibited partial or full conformation-dependence.

Cytokeratin 8 (Cytokeratin 8) Antibody
20-abx009059
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 7 (Cytokeratin 7) Antibody
20-abx009060
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 4 (Cytokeratin 4) Antibody
20-abx121076
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 14 (Cytokeratin 14) Antibody
20-abx121588
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody
abx010621-100ul 100 ul
EUR 493.2

Cytokeratin 15 (Cytokeratin 15) Antibody
20-abx225265
  • EUR 444.00
  • EUR 727.20
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 50 ul

Cytokeratin 14 (Cytokeratin 14) Antibody
abx232195-100ug 100 ug
EUR 577.2

Cytokeratin 14 (Cytokeratin 14) Antibody
abx232196-100ug 100 ug
EUR 610.8

Cytokeratin 14 (Cytokeratin 14) Antibody
abx232197-100ug 100 ug
EUR 661.2

Cytokeratin 15 (Cytokeratin 15) Antibody
abx232198-100ug 100 ug
EUR 577.2

Cytokeratin 15 (Cytokeratin 15) Antibody
abx232199-100ug 100 ug
EUR 610.8

Cytokeratin 4 (Cytokeratin 4) Antibody
abx232214-100ug 100 ug
EUR 577.2

Cytokeratin 7 (Cytokeratin 7) Antibody
abx232217-100ug 100 ug
EUR 610.8

Cytokeratin 7 (Cytokeratin 7) Antibody
abx232218-100ug 100 ug
EUR 661.2

Cytokeratin 8 (Cytokeratin 8) Antibody
abx232221-100ug 100 ug
EUR 577.2

Cytokeratin 8 (Cytokeratin 8) Antibody
abx232222-100ug 100 ug
EUR 661.2

Cytokeratin 8 (Cytokeratin 8) Antibody
abx232223-100ug 100 ug
EUR 661.2

Cytokeratin 8 (Cytokeratin 8) Antibody (FITC)
abx139679-01mg 0.1 mg
EUR 510

Cytokeratin antibody
20R-CP006 100 uL
EUR 550.8
Description: Guinea Pig polyclonal Cytokeratin antibody

Cytokeratin antibody
10R-6655 100 ug
EUR 625.2
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin antibody
10R-6656 100 ug
EUR 625.2
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin 13 antibody
70R-1178 100 ug
EUR 452.4
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the C terminal of KRT13

Cytokeratin 20 antibody
70R-1189 100 ug
EUR 452.4
Description: Rabbit polyclonal Cytokeratin 20 antibody raised against the middle region of KRT20

Cytokeratin 2 antibody
70R-12684 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal Cytokeratin 2 antibody

Cytokeratin 19 antibody
10-1210 500 ug
EUR 522
Description: Mouse monoclonal Cytokeratin 19 antibody

cytokeratin 20 Peptide
43-166P 0.1 mg
EUR 405.6

cytokeratin 20 Peptide
43-167P 0.1 mg
EUR 405.6

cytokeratin 19 Peptide
43-484P 0.1 mg
EUR 405.6

cytokeratin 19 Peptide
43-491P 0.1 mg
EUR 405.6

Cytokeratin 1 antibody
70R-4604 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 1 antibody

Cytokeratin 5 antibody
70R-49975 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 5 antibody

Cytokeratin 7 antibody
70R-49976 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody
70R-49977 100 ul
EUR 344.4
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody
70R-49978 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 10 antibody
70R-49979 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody
70R-49980 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 13 antibody

Cytokeratin 14 antibody
70R-49981 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 14 antibody

Cytokeratin 16 antibody
70R-49982 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 16 antibody

Cytokeratin 17 antibody
70R-49983 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 17 antibody

Cytokeratin 18 antibody
70R-49984 100 ul
EUR 344.4
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody
70R-49985 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 19 antibody
70R-49986 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 19 antibody

Cytokeratin 19 antibody
70R-49987 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 19 antibody

Cytokeratin 84 antibody
70R-49988 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 84 antibody

Cytokeratin 10 antibody
70R-2225 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody
70R-2265 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 13 antibody raised against the N terminal of KRT13

Cytokeratin 16 antibody
70R-2869 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 16 antibody

Cytokeratin 16 antibody
70R-2870 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 16 antibody

Cytokeratin 7 antibody
70R-2930 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 7 antibody raised against the N terminal of KRT7

Cytokeratin 19 antibody
70R-2947 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19

Cytokeratin 23 antibody
70R-2948 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 23 antibody

Cytokeratin 24 antibody
70R-2986 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 24 antibody raised against the middle region of KRT24

Cytokeratin 84 antibody
70R-3002 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 84 antibody raised against the middle region of KRT84

Cytokeratin 19 antibody
70R-3035 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19

Cytokeratin 75 antibody
70R-3038 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the N terminal of KRT75

Cytokeratin 75 antibody
70R-3039 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the middle region of KRT75

Cytokeratin 5 antibody
70R-35563 100 ug
EUR 418.8
Description: Purified Rabbit polyclonal Cytokeratin 5 antibody

Cytokeratin 17 antibody
70R-3229 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 17 antibody raised against the C terminal of KRT17

Cytokeratin 8 antibody
70R-3263 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the middle region of KRT8

Cytokeratin 8 antibody
70R-3292 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 8 antibody raised against the N terminal of KRT8

Cytokeratin 18 antibody
70R-33530 100 ug
EUR 392.4
Description: Rabbit polyclonal Cytokeratin 18 antibody

Cytokeratin 8 antibody
70R-33532 100 ug
EUR 392.4
Description: Rabbit polyclonal Cytokeratin 8 antibody

Cytokeratin 18 antibody
70R-1405 100 ug
EUR 452.4
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the C terminal of KRT18

Cytokeratin 18 antibody
70R-1474 100 ug
EUR 452.4
Description: Rabbit polyclonal Cytokeratin 18 antibody raised against the N terminal of KRT18

Cytokeratin 8 antibody
70R-51570 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody
70R-51571 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 8 antibody

Cytokeratin 18 antibody
70R-51572 100 ul
EUR 344.4
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody
70R-51573 100 ul
EUR 292.8
Description: Purified Polyclonal Cytokeratin 18 antibody

Cytokeratin 10 antibody
70R-13235 100 ul
EUR 516
Description: Affinity purified Rabbit polyclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody
70R-13317 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal Cytokeratin 13 antibody

Cytokeratin 20 antibody
70R-13379 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal Cytokeratin 20 antibody

Cytokeratin 34 antibody
70R-13483 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal Cytokeratin 34 antibody

Cytokeratin 31 antibody
70R-13495 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal Cytokeratin 31 antibody

Cytokeratin 8 antibody
70R-13833 100 ug
EUR 386.4
Description: Affinity purified Rabbit polyclonal Cytokeratin 8 antibody

Cytokeratin 19 antibody
70R-13877 100 ug
EUR 386.4
Description: Affinity purified Rabbit polyclonal Cytokeratin 19 antibody

Cytokeratin 5 Antibody
39247-100ul 100ul
EUR 468

Cytokeratin-1 Antibody
39339-100ul 100ul
EUR 468

Cytokeratin-7 Antibody
48356-100ul 100ul
EUR 399.6

Cytokeratin-7 Antibody
48356-50ul 50ul
EUR 286.8

Cytokeratin 19 Antibody
48622-100ul 100ul
EUR 399.6

Cytokeratin 19 Antibody
48622-50ul 50ul
EUR 286.8

Cytokeratin 20 Antibody
48624-100ul 100ul
EUR 399.6

Cytokeratin 20 Antibody
48624-50ul 50ul
EUR 286.8

Cytokeratin 17 Antibody
48633-100ul 100ul
EUR 399.6

Cytokeratin 17 Antibody
48633-50ul 50ul
EUR 286.8

Cytokeratin 18 Antibody
48696-100ul 100ul
EUR 399.6

Cytokeratin 18 Antibody
48696-50ul 50ul
EUR 286.8

Cytokeratin 5 Antibody
48720-100ul 100ul
EUR 399.6

Cytokeratin 5 Antibody
48720-50ul 50ul
EUR 286.8

Cytokeratin 15 Antibody
48891-100ul 100ul
EUR 399.6

Cytokeratin 15 Antibody
48891-50ul 50ul
EUR 286.8

Cytokeratin 7 Antibody
48899-100ul 100ul
EUR 399.6

Cytokeratin 7 Antibody
48899-50ul 50ul
EUR 286.8

Cytokeratin 10 Antibody
48912-100ul 100ul
EUR 399.6

Cytokeratin 10 Antibody
48912-50ul 50ul
EUR 286.8

Cytokeratin 16 Antibody
48928-100ul 100ul
EUR 399.6

Cytokeratin 16 Antibody
48928-50ul 50ul
EUR 286.8

Cytokeratin 14 Antibody
48956-100ul 100ul
EUR 399.6

Cytokeratin 14 Antibody
48956-50ul 50ul
EUR 286.8

Cytokeratin 5 Antibody
48957-100ul 100ul
EUR 399.6

Cytokeratin 5 Antibody
48957-50ul 50ul
EUR 286.8

Cytokeratin 1 Antibody
49059-100ul 100ul
EUR 399.6

Cytokeratin 1 Antibody
49059-50ul 50ul
EUR 286.8

Cytokeratin 13 Antibody
49069-100ul 100ul
EUR 399.6

Cytokeratin 13 Antibody
49069-50ul 50ul
EUR 286.8

Cytokeratin 6 Antibody
49086-100ul 100ul
EUR 399.6

Cytokeratin 6 Antibody
49086-50ul 50ul
EUR 286.8

Cytokeratin 4 Antibody
49087-100ul 100ul
EUR 399.6

Cytokeratin 4 Antibody
49087-50ul 50ul
EUR 286.8

Cytokeratin 4 Antibody
49108-100ul 100ul
EUR 399.6

Cytokeratin 4 Antibody
49108-50ul 50ul
EUR 286.8

Cytokeratin 9 Antibody
49191-100ul 100ul
EUR 399.6

Cytokeratin 9 Antibody
49191-50ul 50ul
EUR 286.8

Cytokeratin 2e Antibody
49220-100ul 100ul
EUR 399.6

Cytokeratin 2e Antibody
49220-50ul 50ul
EUR 286.8

Cytokeratin 19 Antibody
45016-100ul 100ul
EUR 302.4

Cytokeratin 19 Antibody
45016-50ul 50ul
EUR 224.4

Cytokeratin 14 antibody
20R-CP002 100 ul
EUR 676.8
Description: Guinea Pig polyclonal Cytokeratin 14 antibody

Cytokeratin 5 antibody
20R-CP003 100 uL
EUR 654
Description: Guinea Pig polyclonal Cytokeratin 5 antibody

Cytokeratin 18 protein
30R-AC039 250 ug
EUR 817.2
Description: Purified recombinant Human Cytokeratin 18 protein

Cytokeratin 19 protein
30R-AC040 100 ug
EUR 495.6
Description: Purified recombinant Human Cytokeratin 19 protein

Cytokeratin 8 protein
30R-AC041 100 ug
EUR 501.6
Description: Purified recombinant Human Cytokeratin 8 protein

Cytokeratin 19 antibody
10R-6759 1 ml
EUR 482.4
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 18 antibody
10R-6766 1 ml
EUR 482.4
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin AE1 antibody
10R-6767 1 ml
EUR 508.8
Description: Mouse monoclonal Cytokeratin AE1 antibody

Cytokeratin AE3 antibody
10R-6768 1 ml
EUR 493.2
Description: Mouse monoclonal Cytokeratin AE3 antibody

Cytokeratin antibody cocktail
10R-6769 1 ml
EUR 672
Description: Mouse monoclonal Cytokeratin antibody cocktail

Cytokeratin 7 antibody
10R-7842 100 ug
EUR 386.4
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 18 antibody
10R-7844 100 ug
EUR 366
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 4 antibody
10R-7960 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 4 antibody

Cytokeratin 7 antibody
10R-7962 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 7 antibody
10R-7963 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody
10R-7964 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody
10R-7965 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 10 antibody
10R-7966 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 10 antibody
10R-7967 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody
10R-7969 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 13 antibody

Cytokeratin 14 antibody
10R-7970 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 14 antibody

Cytokeratin 17 antibody
10R-7971 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 17 antibody

Cytokeratin 18 antibody
10R-7972 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody
10R-7973 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody
10R-7974 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 19 antibody
10R-7975 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 6 antibody
10R-7978 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 6 antibody
The bulk (23/31; 74%) of the most important immunoreactive proteins recognized had been small (≤250 aa), and 20/31 (65%) had been predicted to be secreted effectors. Not like the robust linear antibody epitopes beforehand recognized in TRP and OMP orthologs, there have been contrasting variations within the E. ch. and E. ca. antigenic repertoires, epitopes and ortholog immunoreactivity. This examine reveals quite a few beforehand undefined immunodominant and subdominant antigens, and illustrates the breadth, complexity, and variety of immunoreactive proteins/epitopes in Ehrlichia.
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post